Mink Therapeutics Inc · Q2 2026 earnings

Briefing

MiNK Therapeutics reported Q2 2026 financial results with a net loss of $3.1 million and initial positive observations from its randomized Phase 2 trial of agenT-797 in acute lung injury.

MiNK Therapeutics ended the second quarter of 2026 with $8.8 million in cash and a net loss of $3.1 million ($0.62 per share), an improvement from the prior year. The company initiated dosing in its randomized Phase 2 trial C-1300-02 and reported early Day 28 observations showing survival, improved oxygenation, and immune recovery signals with no major adverse events attributed to agenT-797. A paid international named-patient access program was also established in Brazil to generate program revenue while building infrastructure for off-the-shelf cell therapy access.

• Cash and cash equivalents stood at $8.8 million as of June 30, 2026, down from $9.5 million at March 31, 2026.
• Net loss narrowed to $3.1 million ($0.62 per share) in Q2 2026 from $4.2 million ($1.06 per share) in Q2 2025.
• First patients in randomized Phase 2 trial C-1300-02 showed survival at Day 28 with improved oxygenation and infection control.
• Established first paid international named-patient access program in Brazil for agenT-797 under physician-initiated requests.

Headline financials

Revenue & EPS history

Additional data from the C-1300-02 trial expected in early 2027; named-patient program may generate non-promotional income while expanding international infrastructure.